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Background:  Preclinical  drug  vs. food  choice  is  an emerging  group  of drug  self-administration  procedures
that have shown  predictive  validity  to clinical  drug  addiction.  Emerging  data  suggest  that  serotonin
(5-HT)2A receptors  modulate  mesolimbic  dopamine  function,  such  that  5-HT2A antagonists  blunt  the
abuse-related  neurochemical  effects  of monoamine  transporter  substrates,  such  as  amphetamine  or
methamphetamine.  Whether  subchronic  5-HT2A antagonist  treatment  attenuates  methamphetamine
reinforcement  in any  preclinical  drug  self-administration  procedure  is  unknown.  The  study  aim  was
therefore  to  determine  7-day  treatment  effects  with  the  5-HT2A inverse  agonist/antagonist  pimavanserin
on  methamphetamine  vs. food  choice  in  monkeys.
Methods: Behavior  was  maintained  under  a concurrent  schedule  of  food  delivery  (1 g pellets,  ﬁxed-
ratio  100  schedule)  and  intravenous  methamphetamine  injections  (0–0.32  mg/kg/injection,  ﬁxed-ratio
10  schedule)  in  male  rhesus  monkeys  (n  =  3).  Methamphetamine  choice  dose-effect  functions  were
determined  daily  before  and  during  7-day  repeated  pimavanserin  (1.0–10  mg/kg/day,  intramuscular)
treatment  periods.
Results: Under  control  conditions,  increasing  methamphetamine  doses  resulted  in  a  corresponding
increase  in methamphetamine  vs. food  choice.  Repeated  pimavanserin  administration  failed  to  atten-
uate  methamphetamine  choice  and  produce  a reciprocal  increase  in  food  choice  in  any monkey  up to
doses  (3.2–10  mg/kg)  that  suppressed  rates  of  operant  responding  primarily  during  components  where
behavior  was  maintained  by  food  pellets.
Conclusions:  Repeated  5-HT2A receptor  inverse  agonist/antagonist  treatment  did not  attenuate  metham-
phetamine  reinforcement  under  a concurrent  schedule  of  intravenous  methamphetamine  and  food
presentation  in nonhuman  primates.  Overall,  these  results  do not  support  the  therapeutic  potential  of
5-HT2A inverse  agonists/antagonists  as  candidate  medications  for methamphetamine  addiction.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Methamphetamine addiction continues to be an insidious and
global public health problem for which there are no efﬁcacious
pharmacological or behavioral treatment strategies (Brensilver
et al., 2013; Carson and Taylor, 2014). Speciﬁcally, the United
States Drug Enforcement Agency (DEA) reported that metham-
∗ Correspondence address: Department of Pharmacology and Toxicology, Virginia
Commonwealth University, 410 N. 12th St., PO Box 980613, Richmond, VA 23298,
USA.
E-mail address: Matthew.Banks@vcuhealth.org
phetamine was the second most nationally identiﬁed illicit
substance, only behind cannabis (DEA, 2015). Moreover, metham-
phetamine use disorder accounted for the majority of global
persons entering treatment for drug use (UNODC, 2015). In sum-
mary, these epidemiological data support the need for preclinical
research to improve our understanding of the neuropharmaco-
logical mechanisms involved in methamphetamine reinforcement.
This improved mechanistic understanding should facilitate the
development of clinically effective strategies to treat metham-
phetamine addiction.
Previous studies have implicated a role of serotonin (5-
HT)2A receptors in the abuse-related neurochemical and behav-
ioral effects of amphetamine or methamphetamine. For exam-
http://dx.doi.org/10.1016/j.drugalcdep.2016.05.014
0376-8716/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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ple, pretreatment with the 5-HT2A antagonist SR46349-B or
M100,907 attenuated amphetamine-induced increases in extracel-
lular dopamine (DA) levels in the striatum and nucleus accumbens
of rodents (Auclair et al., 2004; Porras et al., 2002) and in the caudate
nucleus of nonhuman primates (Murnane et al., 2013a), respec-
tively. Consistent with these neurochemical results, pretreatment
with the 5-HT2A/2C agonist 5-dimethyoxy-4-iodoamphetamine
(DOI) enhanced methamphetamine discriminative stimulus effects
(Marona-Lewicka and Nichols, 1997; Munzar et al., 2002, 1999),
whereas the 5-HT2A/2C antagonist ketanserin attenuated metham-
phetamine discriminative stimulus effects (Munzar et al., 1999).
Although these data implicate a potential role of 5-HT2A receptors
in methamphetamine abuse-related effects, there are no published
studies determining whether 5-HT2A receptors are necessary for
methamphetamine reinforcement.
The study aim was to determine repeated 5-HT2A inverse
agonist/antagonist pimavanserin treatment effects on metham-
phetamine reinforcement under a methamphetamine vs. food
choice procedure. A preclinical drug vs. food choice procedure was
utilized to investigate methamphetamine reinforcement mecha-
nisms for the following two reasons. First, preclinical drug vs.
food choice procedures have been predictive of human drug abuse
and addiction (Ahmed, 2010; Banks and Negus, 2012). Second,
preclinical drug vs. food choice procedures provide a dependent
measure of behavioral allocation that may  be less sensitive to
reinforcement-independent rate-altering drug effects produced by
treatment drugs that may  have potential as candidate medica-
tions (Banks et al., 2015). Pimavanserin was selected because it
is more selective for 5-HT2A vs. 5-HT2C receptors than M100,907
(Vanover et al., 2006) and has been recently approved by the Food
and Drug Administration for Parkinson’s disease-induced psychosis
treatment (Cummings et al., 2014; Walsh, 2016). If pimavanserin
attenuated methamphetamine choice and produced a correspond-
ing increase in food choice, these preclinical results would suggest
5-HT2A receptors were necessary for methamphetamine reinforce-
ment and support further research evaluating 5-HT2A receptor
inverse agonists/antagonists as candidate anti-methamphetamine
addiction medications.
2. Methods
2.1. Subjects
Studies were conducted in three adult male rhesus mon-
keys (Macaca mulatta) surgically implanted with a double-lumen
catheter (0.76 mm ID × 2.36 mm OD, STI Flow, Morrisville, NC)
inserted into a femoral or jugular vein and who had metham-
phetamine self-administration histories (Banks and Blough, 2015;
Schwienteck and Banks, 2015). Monkeys were maintained on a
diet of fresh fruit and food biscuits (Lab Diet High Protein Monkey
Biscuits #5045, PMI  Nutrition Inc., St. Louis, MO)  delivered after
the behavioral session. Water was continuously available in the
housing chamber and a 12 h light-dark cycle was  in effect. Mon-
keys had visual, auditory and olfactory contact with other monkeys
throughout the study. Operant procedures and foraging toys were
provided for environmental manipulation and enrichment. Videos
or music was also played daily in animal housing rooms to pro-
vide additional environmental enrichment. Animal research and
maintenance were conducted according to the Guide for the Care
and Use of Laboratory Animals (National Research Council, 2011).
Animal facilities were licensed by the United States Department of
Agriculture and accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care. The Institutional Animal
Care and Use Committee approved both the research and environ-
mental enrichment protocols.
2.2. Apparatus
The housing chamber served as the experimental chamber
and was  equipped with a custom operant panel, a pellet dis-
penser (Med Associates, Model ENV-203-1000, St. Albans, VT), and
two syringe pumps (Model PHM-108, Med  Associates). One “self-
administration” pump delivered contingent methamphetamine
injections through one catheter lumen. The second “treatment”
pump delivered a 0.1 mL  noncontingent saline infusion through the
second catheter lumen at a programmed rate of every 20 min  from
1200 each day until 1100 the following morning. The intravenous
catheter was  protected by a customized stainless steel tether and
jacket system (Lomir Biomedical, Malone, NY) that permitted mon-
keys to move freely within the home chamber. Catheter patency
was periodically evaluated by intravenous ketamine (5 mg/kg)
administration through one lumen of the double-lumen catheter.
The catheter was  considered patent if intravenous ketamine admin-
istration produced muscle tone loss within 10 s.
2.3. Methamphetamine vs. food choice procedure
Daily experimental sessions were conducted from 0900 to
1100 h in each monkey’s home chamber as described previ-
ously (Banks and Blough, 2015). The terminal choice procedure
consisted of ﬁve 20 min  components, with a different unit metham-
phetamine dose available during each successive component (0,
0.01, 0.032, 0.1, and 0.32 mg/kg/injection during components 1–5,
respectively). Manipulating the injection volume controlled the
methamphetamine dose (0, 0.03, 0.1, 0.3, and 1.0 mL/injection,
respectively). Components were separated by 5 min timeout
periods. During each component, the left, food-associated key
was transilluminated red, and completion of the FR require-
ment (FR100) resulted in 1 g food pellet delivery. The right,
methamphetamine-associated key was  transilluminated green,
and completion of the FR requirement (FR10) resulted in delivery of
the intravenous unit methamphetamine dose available during that
component. Stimulus lights for the methamphetamine-associated
key were ﬂashed on and off in 3 s cycles, and longer ﬂashes
were associated with larger methamphetamine doses. Monkeys
could complete up to a total of 10 ratio requirements between
the food- and methamphetamine-associated keys. Responding on
either key reset the ratio requirement on the other key. Each ratio
requirement completion initiated a 30 s timeout, during which
all stimulus lights were turned off, and responding had no pro-
grammed consequences. Choice behavior was  considered stable
when the lowest unit methamphetamine dose maintaining greater
than 80% methamphetamine vs. food choice varied by ≤0.5 log units
for 3 consecutive days.
Once methamphetamine vs. food choice was stable, test ses-
sions were conducted to determine 7-day repeated pimavanserin
(1–10 mg/kg, IM)  treatment effects on methamphetamine vs. food
choice. Pimavanserin was  administered between 0755 and 0805 h,
approximately 60 min  before the 0900 h start of the behavioral ses-
sion. Pimavanserin treatment was tested up to doses that decreased
either methamphetamine choice or operant responding. The 3-
day saline infusion period before each test drug treatment was
used as the “baseline.” At the conclusion of each 7-day treatment
period, intramuscular injections were terminated for at least 4 days
and until methamphetamine vs. food choice had returned to pre-
treatment levels. Pimavanserin doses were counterbalanced across
subjects.
2.4. Data analysis
The primary dependent measures were (1) percent metham-
phetamine choice, deﬁned as (number of ratios completed on
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the methamphetamine-associated key ÷ total number of ratios
completed)*100 and (2) number of ratio requirements (hereafter
referred to as “choices”) completed. The last 3-day mean of each
experimental condition for each monkey for each dependent mea-
sure was then plotted as a function of unit methamphetamine dose
during the behavioral session. Results were analyzed using a lin-
ear mixed-effects analysis with unit methamphetamine dose and
pimavanserin dose as the ﬁxed main effects and subjects as the
random effect. Post-hoc comparisons against baseline conditions
within a given methamphetamine dose were performed using the
Dunnett’s test following a signiﬁcant main effect of pimavanserin
dose or methamphetamine dose × pimavanserin dose interaction.
The criterion for signiﬁcance was set a priori at the 95% conﬁdence
level (p < 0.05). All analyses were conducted using JMP  Pro 12.2,
SAS, Cary, NC.
2.5. Drugs
(+)-Methamphetamine HCl and pimavanserin l-tartrate were
provided by the National Institute on Drug Abuse Drug Supply Pro-
gram (Bethesda, MD). All drug doses were expressed as the salt
forms listed above and all drug solutions were passed through a
sterile 0.2 m ﬁlter (Millipore, Billerica, MA)  before administration.
3. Results
3.1. Effects of pimavanserin on methamphetamine vs. food choice
Under control conditions during which saline was  continu-
ously infused through the treatment lumen “baseline”, increasing
methamphetamine doses resulted in behavioral reallocation away
from the food-associated key and towards the methamphetamine-
associated key (Fig. 1). Repeated pimavanserin treatment failed
to signiﬁcantly alter either methamphetamine vs. food choice or
choices completed per component (Fig. 1). Due to individual sub-
ject sensitivity to pimavanserin potency to produce rate-altering
effects, individual data are shown in Fig. 2. In monkey M1515,
repeated pimavanserin treatment had no effect up to pimavanserin
doses (10 mg/kg) that decreased rates of operant responding
primarily during components maintained by food. Furthermore,
repeated 10 mg/kg pimavanserin treatment also decreased body
weight in this monkey by more than 1 kg. In both monkey M1516
and M1523, a pimavanserin dose of 3.2 mg/kg decreased rates of
operant responding to such an extent that larger pimavanserin
doses were not tested.
4. Discussion
The study aim was to determine whether repeated 5-HT2A
inverse agonist/antagonist pimavanserin administration decreased
methamphetamine reinforcement in monkeys. The main ﬁnding
was that pimavanserin did not attenuate methamphetamine choice
and produce a corresponding increase in food choice in any monkey
up to doses that decreased operant response rates and produced
signiﬁcant weight loss. Overall, the present results do not support
the potential clinical utility of 5-HT2A inverse agonists/antagonists
as anti-methamphetamine addiction medications.
The present behavioral results were inconsistent with previ-
ous neurochemical (Auclair et al., 2004; Murnane et al., 2013a;
Porras et al., 2002) and behavioral (Munzar et al., 1999) results
demonstrating 5-HT2A antagonists attenuated amphetamine or
methamphetamine abuse-related effects. There are three potential
reasons for these inconsistent results. First, potential species dif-
ferences between rats and nonhuman primates in either 5-HT2A or
methamphetamine neuropharmacology could explain these incon-
Fig. 1. Effects of 7-day repeated pimavanserin (1.0–3.2 mg/kg, intramuscular) treat-
ment on choice between methamphetamine and food in rhesus monkeys (n = 3).
Abscissae: unit dose methamphetamine in mg/kg/injection. Top ordinate: per-
cent methamphetamine choice. Bottom ordinate: number of ratio requirements
(choices) completed per choice session component. All points represent mean ± SEM
obtained during days 5–7 of each 7-day treatment period. Numbers in parenthe-
ses  denote the number of monkeys contributing to that data point if less than the
maximal number of monkeys tested and indicate a component where one or more
monkeys failed to complete at least one ratio requirement.
sistent results. A second potential explanation could be related
to differences in dosing regimens. For example, previous stud-
ies utilized acute dosing regimens whereas the present study
determined 5-HT2A inverse agonist/antagonist effects under a
repeated subchronic dosing regimen. Examination of pimavanserin
treatment days 1–3 did not reveal a rightward shift in the metham-
phetamine choice dose-effect function in any monkey (data not
shown). A third potential explanation could be related to dif-
ferences in experimental dependent measures. Previous studies
determined 5-HT2A antagonist effects on amphetamine-induced
dopamine release in either nucleus accumbens (Auclair et al.,
2004; Porras et al., 2002) or caudate nucleus (Murnane et al.,
2013a) and methamphetamine discriminative stimulus effects
(Munzar et al., 1999); whereas the present study determined
5-HT2A inverse agonist/antagonist effects on methamphetamine
reinforcement. However, repeated pimavanserin treatment effects
on methamphetamine self-administration were consistent with
previous studies evaluating ketanserin and M100,907 acute pre-
treatments on cocaine self-administration (Fantegrossi et al., 2002;
Murnane et al., 2013b). Overall, the present results and the previous
literature highlight the importance of repeated pharmacological
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Fig. 2. Effects of 7-day repeated pimavanserin (1.0–3.2 mg/kg, intramuscular) treatment on choice between methamphetamine and food in individual rhesus monkeys.
Abscissae: unit dose methamphetamine in mg/kg/injection. Left ordinates: percent methamphetamine choice. Right ordinates: number of ratio requirements (choices)
completed per choice session component. All points represent mean ± SEM obtained during days 5–7 of each 7-day treatment period. 10 mg/kg pimavanserin treatment was
only  tested in M1515. Missing data points indicate that a monkey failed to complete at least one ratio requirement during that component.
pretreatments and determination of treatment effects on multiple
dependent measures to characterize candidate medication treat-
ment efﬁcacy.
Conceptually, 5-HT2A receptor antagonists represent an
“antagonist-like” pharmacotherapeutic approach for metham-
phetamine addiction with the neurobiological aim of blunting
methamphetamine-induced nucleus accumbens dopamine release
and corresponding reinforcing effects. The present behavioral
results suggest this may  not be a therapeutically advantageous
treatment option for methamphetamine addiction. The present
results are consistent with previous methamphetamine vs. food
choice studies in nonhuman primates evaluating “antagonist-
like” pharmacological treatments such as dopamine antagonists
PG01037, buspirone, and risperidone or the dopamine D3 par-
tial agonist PG619 (Banks and Blough, 2015; John et al., 2015a,
2015b). Furthermore, both the dopamine partial agonist arip-
iprazole and the dopamine antagonist risperidone have failed
to reduce methamphetamine choice in the human laboratory
(Stoops et al., 2013) or methamphetamine use in clinical trials
(Cofﬁn et al., 2013; Nejtek et al., 2008; Tiihonen et al., 2007).
Moreover, “antagonist-like” approaches have not been successful
pharmacotherapeutic strategies to treat amphetamine-type or
cocaine addictions based on a recent meta-analysis (Kishi et al.,
2013). In summary, we interpret this scientiﬁc literature to suggest
methamphetamine addiction medications development might
beneﬁt from a paradigm shift to novel “agonist-like” therapies that
264 M.L. Banks / Drug and Alcohol Dependence 165 (2016) 260–264
both decrease methamphetamine use and promote more adaptive
behavior maintained by alternative non-drug reinforcers.
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